Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/30/16
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 06/30/16
End: 06/30/18
Due: 06/30/19
Phase: N/A
Priority: Normal
Start: 04/30/21
End: 01/01/26
Due: 01/01/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma | NCT02856997 | Yuankai Shi | user2@example.com | None | 2016-09-30 | - | - | - | - | 2025-07-14 |
| Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer | NCT02815007 | Yuankai Shi | user2@example.com | None | 2016-06-30 | 2018-06-30 | 2019-06-30 | - | - | 2025-07-14 |
| Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China | NCT04857164 | Yuankai Shi | user2@example.com | None | 2021-04-30 | 2026-01-01 | 2027-01-01 | - | - | 2025-07-14 |